| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $15.5M | -46.6% |
| SG&A Expense | $16.0M | +17.2% |
| Operating Income | -$31.5M | +26.2% |
| Pre-tax Income | -$30.1M | +25.1% |
| Net Income | -$30.1M | +25.1% |
| EPS (Basic) | -$15.85 | -738.6% |
| EPS (Diluted) | -$15.85 | -738.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $5.0M | -61.0% |
| Current Assets | $6.4M | -56.5% |
| Total Assets | $8.0M | -56.1% |
| Current Liabilities | $5.3M | -5.8% |
| Total Liabilities | $5.3M | -24.5% |
| Stockholders' Equity | $2.7M | -75.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$26.1M | +35.4% |
| Investing Cash Flow | $212K | -99.5% |
| Financing Cash Flow | $18.0M | — |